Clinical trial
Comparison of Telavancin and Vancomycin for Hospital-acquired Pneumonia Due to…
NCT00124020 · Cumberland Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00124020 |
|---|---|
| Title | Comparison of Telavancin and Vancomycin for Hospital-acquired Pneumonia Due to Methicillin-resistant Staphylococcus Aureus |
| Official title | A Phase 3, Randomized, Double-Blind, Parallel-Group, Multinational Trial of Intravenous Telavancin Versus Vancomycin for Treatment of Hospital-Acquired Pneumonia With a Focus on Patients With Infections Due to Methicillin-Resistant Staphylococcus Aureus |
| Acronym | ATTAIN2 |
| Lead sponsor | Cumberland Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Bacterial Pneumonia |
| Intervention type | Drug |
| Interventions | Telavancin, Vancomycin |
| Enrollment | 771 |
| Start date | Jan 1, 2005 |
| Primary completion | May 1, 2007 |
| Completion | May 1, 2007 |
| First posted | Jul 26, 2005 |
| Last update posted | Jan 16, 2019 |
| Countries | Israel |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: